Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability
Investigative Ophthalmology & Visual Science2018Vol. 59(15), pp. 5836–5836
Citations Over TimeTop 10% of 2018 papers
Gerard A. Rodrigues, Matthew D. Mason, Lori‐Ann Christie, Candice Hansen, Lisa M. Hernández, James A. Burke, Keith A. Luhrs, Thomas C. Hohman
Abstract
These data support the testing of abicipar as a treatment for retinal diseases characterized by neovascularization and vascular leak.
Related Papers
- Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.(1998)
- → Factors regulating the expression of vascular permeability/vascular endothelial growth factor by human vascular tissues(1997)40 cited
- → Eucalyptus globulus essential oil increases neovascularization and vascular endothelial growth factor expression in male Wistar rats exposed to UVB(2021)2 cited
- → Increased levels of vascular endothelial growth factor in BALF in asthmatic rats(2010)
- Advances in the Research of Vascular Endothelial Growth Factor(2012)